VICORE PHARMA HOLDING AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.9 SEK | -0.75% |
|
+10.19% | +40.34% |
| 05-07 | Vicore Pharma Holding AB Announces Board Appointments | CI |
| 05-03 | Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 737.6 | 1,903 | 998.9 | 1,465 | 1,584 | 2,223 | - | - |
| Enterprise Value (EV) 1 | 550 | 1,655 | 704.7 | 1,203 | 1,251 | 1,919 | 2,013 | 2,013 |
| P/E ratio | -6.81 x | -11.6 x | -3.28 x | -4.49 x | -4.4 x | -14.5 x | -8.46 x | -16.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 42.8 x | 5.66 x | 28.5 x |
| EV / Revenue | - | - | - | - | - | 36.9 x | 5.12 x | 25.8 x |
| EV / EBITDA | -5.93 x | -11.1 x | -2.42 x | -4.19 x | -4.89 x | -8.62 x | -11.6 x | -11.4 x |
| EV / FCF | -3.35 x | -13.3 x | -2.59 x | -5.33 x | -3.17 x | -39.2 x | -5.99 x | -10.1 x |
| FCF Yield | -29.8% | -7.51% | -38.6% | -18.8% | -31.5% | -2.55% | -16.7% | -9.89% |
| Price to Book | - | 5.37 x | 2.61 x | 5.07 x | 3.01 x | 7.54 x | 12.7 x | 29.2 x |
| Nbr of stocks (in thousands) | 50,175 | 60,418 | 71,760 | 81,848 | 111,723 | 111,723 | - | - |
| Reference price 2 | 14.70 | 31.50 | 13.92 | 17.90 | 14.18 | 19.90 | 19.90 | 19.90 |
| Announcement Date | 20-02-28 | 21-02-26 | 22-02-25 | 23-02-28 | 24-02-28 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 52 | 393.1 | 78 |
| EBITDA 1 | -92.68 | -149.5 | -291.2 | -287.1 | -255.5 | -222.7 | -173.7 | -176.4 |
| EBIT 1 | -94.01 | -149.5 | -294.8 | -290.7 | -321.5 | -223.9 | -174.5 | -176.4 |
| Operating Margin | - | - | - | - | - | -430.46% | -44.39% | -226.11% |
| Earnings before Tax (EBT) 1 | -93.33 | -147.3 | -296.7 | -288.8 | -311.3 | -223.4 | -173.6 | -175.4 |
| Net income 1 | -93.08 | -146.9 | -296.5 | -288.4 | -310.9 | -223.1 | -173.4 | -175.2 |
| Net margin | - | - | - | - | - | -429.03% | -44.1% | -224.64% |
| EPS 2 | -2.160 | -2.710 | -4.250 | -3.990 | -3.220 | -1.374 | -2.352 | -1.215 |
| Free Cash Flow 1 | -164.1 | -124.3 | -272.2 | -225.9 | -394 | -49 | -336 | -199 |
| FCF margin | - | - | - | - | - | -94.22% | -85.47% | -255.13% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20-02-28 | 21-02-26 | 22-02-25 | 23-02-28 | 24-02-28 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | - | -63.95 | -65.18 | -68.96 | -64.22 | -69.17 |
| EBIT 1 | - | -64.9 | -66.1 | -69.8 | -65.06 | -120.6 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -80.29 | - | -66.38 | -69.3 | -63.66 | -112 |
| Net income 1 | -80.4 | -65.9 | -66.3 | -69.2 | -63.56 | -111.9 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -1.120 | - | -0.8100 | -0.8500 | -0.5800 | -1.000 |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 22-02-25 | 22-08-25 | 23-05-04 | 23-08-24 | 23-11-02 | 24-02-28 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 188 | 249 | 294 | 262 | 334 | 304 | 210 | 211 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -164 | -124 | -272 | -226 | -394 | -49 | -336 | -199 |
| ROE (net income / shareholders' equity) | -30.7% | -43.4% | -80.4% | -85.8% | -83.5% | -58.6% | -84% | -19.3% |
| ROA (Net income/ Total Assets) | -29% | -39.3% | -69.1% | -73% | -74.5% | -55.5% | -126% | -16.8% |
| Assets 1 | 321.4 | 373.9 | 428.9 | 394.8 | 417.1 | 402.2 | 137.4 | 1,043 |
| Book Value Per Share 2 | - | 5.870 | 5.340 | 3.530 | 4.720 | 2.640 | 1.570 | 0.6800 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 20-02-28 | 21-02-26 | 22-02-25 | 23-02-28 | 24-02-28 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
19.9
SEK
Average target price
61.5
SEK
Spread / Average Target
+209.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.34% | 204M | |
| +2.93% | 108B | |
| +7.02% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- VICO Stock
- Financials Vicore Pharma Holding AB